Gastroesophageal reflux disease

Canadian Journal of Gastroenterology

Volumn 12, Issue 2, 1998, Pages 107-108

  Williams, C N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

BARRETT ESOPHAGUS; ESOPHAGITIS; ESOPHAGUS PH; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATUS HERNIA; HUMAN; LIFESTYLE; LOWER ESOPHAGUS SPHINCTER; MAINTENANCE THERAPY; PATIENT EDUCATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; STOMACH EMPTYING; STOMACH FUNDOPLICATION; WEIGHT REDUCTION;

BARRETT ESOPHAGUS; ESOPHAGEAL STENOSIS; ESOPHAGITIS, PEPTIC; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; LIFE STYLE; PROTON PUMPS; RISK FACTORS;

EID: 0031934603     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Anvari M, Allen C, Borm A. Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy. Br J Surg 1995;82:938-42.
2. Berstad A, Hatlebakk JG. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Aliment Pharmacol Ther 1993;7(Suppl 1):34-6.
3. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Study Group. Am J Gastroenterol 1996;91:1749-57.
4. Damman H. Pantoprazole is a highly effective option for gastric acid-related disorders. Drugs Ther Perspect 1996;8:1-5.
5. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995;155:2165-73.
6. 2 receptor antagonists with lansoprazole, a new H+/ K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group. Am J Gastroenterol 1993;88:1212-7.
7. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med 1996;156:477-84.
8. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:46-82.
9. Hassal E. Wrap session: is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children? Am J Gastroenterol 1995;90:1212-20.
10. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
11. Luostarinen M, Isolauri J, Laitinen J, et al. Fate of Nissen fundoplication after 20 years. A clinical, endoscopical, and functional analysis. Gut 1993;34:1015-20.
12. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med 1997;36:924-32.
13. Mundo F, Felix R, Aguilar J, et al. Omeprazole vs ranitidine plus cisapride in the treatment of reflux esophagitis: comparative endoscopic study. Am J Gastroenterol 1992;87:1254.
14. Orr WC. Maintenance therapy in gastroesophageal reflux disease. Hosp Formul 1992;27:504-8.
15. Peters JH, Heimbucher J, Kauer WK, et al. Clinical and physiologic comparison of laparoscopic and open Nissen fundoplication. J Am Coll Surg 1995;180:385-93.
16. Robinson M, Deckator DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive esophagitis. Aliment Pharmacol Ther 1993;7:67-73.
17. Spechler SJ. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 1992;326:786-92.
18. Swarbrick ET, Gough AL, Forster CS, et al. Prevention of recurrence of oesophageal stricture: a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996;8:431-8.
19. Wetscher GJ, Profanter C, Gadenstatter M, et al. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor body motility. Langenbecks Arch Chir 1997;382:95-9.